Program International Investor meeting Life Sciences & Biotech March 13 - Amsterdam

1:30 - 2:00 pm	Walk-in
2:00 - 2:10 pm	Opening Remarks & Key Insights on legal aspects in Life Sciences innovation" by Arjan Reijn, Legal Director Life Sciences Pinsent Masons
2:05 - 2:10 pm	Introduction ESIL program by Reginald Vossen, President Business Angels Europe
2:10 - 2:55 pm	 Investor-expert panel members introduce themselves and showcase their Life Sciences investment strategies and their critical factors for a successful exit. Dr. Ricardo Perdigão Henriques, Biovance Capital Portugal Alfons Boltjes, Bolwork International Investments, Dubai Johan Bender, Bender Analytical Holding BV
2:55 - 3:07 pm	Company 1
3:07 - 3:19 pm	Company 2
3:19 - 3:31 pm	Company 3
	company o
3:31 - 3:43 pm	Company 4
3:31 - 3:43 pm 3:43 - 3:55 pm	
•	Company 4
3:43 - 3:55 pm	Company 4 Company 5

Pitch sessions: companies will pitch 7 minutes, followed by 5 minutes of constructive feedback from the investor-expert panel.

About Pinsent Mason, our host for this Investor meeting - Pinsent Masons is an international law firm known for its sector expertise, entrepreneurial spirit, and innovation. The firm develops groundbreaking solutions in legal tech and project management and has established a dynamic hub for freelance lawyers. Pinsent Masons is a global leader in diversity and inclusion.

With over 4,300 employees in 27 locations worldwide, Pinsent Masons offers a wide range of professional services. The firm combines sector specialization, entrepreneurial spirit, and innovation to achieve the best results and handle complex, cross-border matters effortlessly.

Pinsent Masons specializes in the sectors of Energy, Financial Services, Infrastructure & Real Estate, Retail, Sport & Leisure, and Technology, Science & Industry. This expertise enables the firm to provide customized solutions that are efficient and effective, giving clients a competitive advantage.

In Amsterdam, Pinsent Masons is primarily active in Transactional Services (Corporate, Tax, Employment, Finance & Banking) and Risk Advisory Services (IP, TMT, Litigation & Regulatory).














Dr. Ricardo Perdigão Henriques is the Managing Partner of Biovance Capital, a new €51M fund to invest in early-stage biotech companies across Europe. He is a Harvard and MITeducated scientist turned investor with experience in scientific research, drug development, venture capital licensing, business development, and market analysis.

Ricardo has developed his career in the biomedical sector in both the USA and Portugal. Prior to Biovance Capital, he was the CEO of Bionova Capital, a venture capital firm that invested in health startups across Europe. At Bionova, he invested in the oncology startup CellmAbs, which was sold to BioNTech for potentially more than £1 billion, being the largest-ever biotech deal in Portugal.

He performed his PhD work at the Harvard Medical School in the field of microRNAs. Previously, he was a researcher at the Massachusetts Institute of Technology where he developed micro-bioreactors as a new tool for high-throughput screening. Ricardo holds a B.Sc. in Biochemistry and a Ph.D. in Molecular Biology, both approved with the Highest Honors.





Alfons Boltjes is a Dutch entrepreneur and investor with a broad background in various industries, including IT, software, digital media, e-commerce, pharmaceuticals, biotechnology, healthcare, and food. He has co-founded and invested in multiple startups, demonstrating a strong commitment to innovation and business development. In 2020, Boltjes co-founded EqmmtRentals, a peer-to-peer rental platform designed to monetize unused tools and machinery by connecting lessors and users for flexible transactions. Throughout his career, Boltjes has held various leadership roles, including founder and director positions at Freya Pharma Solutions and Bulwark Holding. He has also served as an interim manager and consultant at Bolwork BV, a venture partner at Venturerock, and a senior partner at 2C&More.

Boltjes's educational background includes a Bachelor's degree in International Marketing from Saxion University of Applied Sciences. His extensive experience and diverse skill set have established him as a notable figure in the Dutch entrepreneurial and investment landscape with a focus on Healthcare and Life Sciences.





Johan Bender is a Dutch pharmacist and entrepreneur, best known as the founder and Chief Technology Officer (CTO) of GATT Technologies, a medical device company specializing in hemostatic solutions. He earned his Master of Pharmacy degree from Utrecht University in 1995. Following his graduation, Bender worked in research and development roles at Pharmachemie (TEVA) and Medinet CRL (Analytico). In 2000, he became the managing director of Bactimm and later co-owned Bactimm/Farmalyse, companies providing contract laboratory services to the pharmaceutical industry. These ventures were sold to aap biolmplants AG in 2007.

In 2011, Bender founded GATT Technologies, inspired by the potential of a synthetic polymer for medical applications. Under his leadership, the company developed the GATT-Patch, a fastacting hemostatic sealing patch designed to control severe surgical bleeding and prevent organ leakage. This innovation attracted significant attention, leading to the acquisition of GATT Technologies by Ethicon, a subsidiary of Johnson & Johnson, in May 2022.

